Immunosuppressive CD14+HLA-DRlow/- monocytes in B-cell non-Hodgkin lymphoma

Yi Lin, Michael Gustafson, Peggy A. Bulur, Dennis A. Gastineau, Thomas Elmer Witzig, Allan B Dietz

Research output: Contribution to journalArticle

148 Citations (Scopus)

Abstract

Immunosuppression is a known risk factor for B-cell non-Hodgkin lymphoma (NHL), yet mechanisms of tumor-associated immunosuppression remain to be fully characterized. We examined the immunophenotype of 40 NHL patients and 27 age-matched healthy volunteers to better understand systemic immune suppression. NHL peripheral blood mononuclear cells had significantly decreased interferon-γ production and proliferation. This suppression was not the result of regulatory T cells, interleukin-6 or interleukin-10, as these factors were not different between NHL and healthy volunteers (controls). We were able to restore T-cell proliferation by removing NHL monocytes, suggesting that these monocytes are suppressive. This suppression was mediated in part through arginine metabolism as exogenous arginine supplementation partially overcame monocytes' suppression of T-cell proliferation in vitro and NHL patients had elevated arginase I in their plasma. NHL monocytes had impaired STAT1 phosphorylation and interferon-α production to CpG stimulation and a dendritic cell differentiation deficiency. Further studies demonstrated that monocytes from NHL patients had decreased HLA-DR and Tumor necrosis factor-α receptor II (CD120b) expression compared with controls (CD14 +HLA-DRlow/-CD120blow). Patients with increased ratios of CD14+HLA-DRlow/- monocytes had more aggressive disease and suppressed immune functions. In summary, we report that CD14 +HLA-DRlow/- monocytes are a major and multifactorial contributor to systemic immunosuppression in NHL.

Original languageEnglish (US)
Pages (from-to)872-881
Number of pages10
JournalBlood
Volume117
Issue number3
DOIs
StatePublished - Jan 20 2011

Fingerprint

T-cells
B-Cell Lymphoma
Immunosuppressive Agents
Non-Hodgkin's Lymphoma
Monocytes
Cells
Cell proliferation
Interferons
Arginine
Arginase
Phosphorylation
Tumor Necrosis Factor Receptors
HLA-DR Antigens
Metabolism
Interleukin-10
Immunosuppression
Tumors
Interleukin-6
Blood
Plasmas

ASJC Scopus subject areas

  • Hematology
  • Biochemistry
  • Cell Biology
  • Immunology

Cite this

Immunosuppressive CD14+HLA-DRlow/- monocytes in B-cell non-Hodgkin lymphoma. / Lin, Yi; Gustafson, Michael; Bulur, Peggy A.; Gastineau, Dennis A.; Witzig, Thomas Elmer; Dietz, Allan B.

In: Blood, Vol. 117, No. 3, 20.01.2011, p. 872-881.

Research output: Contribution to journalArticle

@article{65a2767b3e924ec49f114fb90bf81829,
title = "Immunosuppressive CD14+HLA-DRlow/- monocytes in B-cell non-Hodgkin lymphoma",
abstract = "Immunosuppression is a known risk factor for B-cell non-Hodgkin lymphoma (NHL), yet mechanisms of tumor-associated immunosuppression remain to be fully characterized. We examined the immunophenotype of 40 NHL patients and 27 age-matched healthy volunteers to better understand systemic immune suppression. NHL peripheral blood mononuclear cells had significantly decreased interferon-γ production and proliferation. This suppression was not the result of regulatory T cells, interleukin-6 or interleukin-10, as these factors were not different between NHL and healthy volunteers (controls). We were able to restore T-cell proliferation by removing NHL monocytes, suggesting that these monocytes are suppressive. This suppression was mediated in part through arginine metabolism as exogenous arginine supplementation partially overcame monocytes' suppression of T-cell proliferation in vitro and NHL patients had elevated arginase I in their plasma. NHL monocytes had impaired STAT1 phosphorylation and interferon-α production to CpG stimulation and a dendritic cell differentiation deficiency. Further studies demonstrated that monocytes from NHL patients had decreased HLA-DR and Tumor necrosis factor-α receptor II (CD120b) expression compared with controls (CD14 +HLA-DRlow/-CD120blow). Patients with increased ratios of CD14+HLA-DRlow/- monocytes had more aggressive disease and suppressed immune functions. In summary, we report that CD14 +HLA-DRlow/- monocytes are a major and multifactorial contributor to systemic immunosuppression in NHL.",
author = "Yi Lin and Michael Gustafson and Bulur, {Peggy A.} and Gastineau, {Dennis A.} and Witzig, {Thomas Elmer} and Dietz, {Allan B}",
year = "2011",
month = "1",
day = "20",
doi = "10.1182/blood-2010-05-283820",
language = "English (US)",
volume = "117",
pages = "872--881",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "3",

}

TY - JOUR

T1 - Immunosuppressive CD14+HLA-DRlow/- monocytes in B-cell non-Hodgkin lymphoma

AU - Lin, Yi

AU - Gustafson, Michael

AU - Bulur, Peggy A.

AU - Gastineau, Dennis A.

AU - Witzig, Thomas Elmer

AU - Dietz, Allan B

PY - 2011/1/20

Y1 - 2011/1/20

N2 - Immunosuppression is a known risk factor for B-cell non-Hodgkin lymphoma (NHL), yet mechanisms of tumor-associated immunosuppression remain to be fully characterized. We examined the immunophenotype of 40 NHL patients and 27 age-matched healthy volunteers to better understand systemic immune suppression. NHL peripheral blood mononuclear cells had significantly decreased interferon-γ production and proliferation. This suppression was not the result of regulatory T cells, interleukin-6 or interleukin-10, as these factors were not different between NHL and healthy volunteers (controls). We were able to restore T-cell proliferation by removing NHL monocytes, suggesting that these monocytes are suppressive. This suppression was mediated in part through arginine metabolism as exogenous arginine supplementation partially overcame monocytes' suppression of T-cell proliferation in vitro and NHL patients had elevated arginase I in their plasma. NHL monocytes had impaired STAT1 phosphorylation and interferon-α production to CpG stimulation and a dendritic cell differentiation deficiency. Further studies demonstrated that monocytes from NHL patients had decreased HLA-DR and Tumor necrosis factor-α receptor II (CD120b) expression compared with controls (CD14 +HLA-DRlow/-CD120blow). Patients with increased ratios of CD14+HLA-DRlow/- monocytes had more aggressive disease and suppressed immune functions. In summary, we report that CD14 +HLA-DRlow/- monocytes are a major and multifactorial contributor to systemic immunosuppression in NHL.

AB - Immunosuppression is a known risk factor for B-cell non-Hodgkin lymphoma (NHL), yet mechanisms of tumor-associated immunosuppression remain to be fully characterized. We examined the immunophenotype of 40 NHL patients and 27 age-matched healthy volunteers to better understand systemic immune suppression. NHL peripheral blood mononuclear cells had significantly decreased interferon-γ production and proliferation. This suppression was not the result of regulatory T cells, interleukin-6 or interleukin-10, as these factors were not different between NHL and healthy volunteers (controls). We were able to restore T-cell proliferation by removing NHL monocytes, suggesting that these monocytes are suppressive. This suppression was mediated in part through arginine metabolism as exogenous arginine supplementation partially overcame monocytes' suppression of T-cell proliferation in vitro and NHL patients had elevated arginase I in their plasma. NHL monocytes had impaired STAT1 phosphorylation and interferon-α production to CpG stimulation and a dendritic cell differentiation deficiency. Further studies demonstrated that monocytes from NHL patients had decreased HLA-DR and Tumor necrosis factor-α receptor II (CD120b) expression compared with controls (CD14 +HLA-DRlow/-CD120blow). Patients with increased ratios of CD14+HLA-DRlow/- monocytes had more aggressive disease and suppressed immune functions. In summary, we report that CD14 +HLA-DRlow/- monocytes are a major and multifactorial contributor to systemic immunosuppression in NHL.

UR - http://www.scopus.com/inward/record.url?scp=78751689059&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78751689059&partnerID=8YFLogxK

U2 - 10.1182/blood-2010-05-283820

DO - 10.1182/blood-2010-05-283820

M3 - Article

C2 - 21063024

AN - SCOPUS:78751689059

VL - 117

SP - 872

EP - 881

JO - Blood

JF - Blood

SN - 0006-4971

IS - 3

ER -